Bank of Montreal Can Acquires 17,386 Shares of Ionis Pharmaceuticals Inc (IONS)

Share on StockTwits

Bank of Montreal Can lifted its holdings in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 95.2% in the fourth quarter, HoldingsChannel reports. The firm owned 35,651 shares of the company’s stock after purchasing an additional 17,386 shares during the quarter. Bank of Montreal Can’s holdings in Ionis Pharmaceuticals were worth $1,928,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. FMR LLC grew its holdings in shares of Ionis Pharmaceuticals by 8.7% in the third quarter. FMR LLC now owns 20,463,839 shares of the company’s stock valued at $1,055,525,000 after purchasing an additional 1,635,782 shares in the last quarter. Vanguard Group Inc. lifted its position in Ionis Pharmaceuticals by 1.4% in the third quarter. Vanguard Group Inc. now owns 11,091,298 shares of the company’s stock worth $572,089,000 after buying an additional 157,770 shares during the last quarter. Vanguard Group Inc lifted its position in Ionis Pharmaceuticals by 1.4% in the third quarter. Vanguard Group Inc now owns 11,091,298 shares of the company’s stock worth $572,089,000 after buying an additional 157,770 shares during the last quarter. BlackRock Inc. lifted its position in Ionis Pharmaceuticals by 5.8% in the third quarter. BlackRock Inc. now owns 7,463,257 shares of the company’s stock worth $384,955,000 after buying an additional 408,678 shares during the last quarter. Finally, First Trust Advisors LP lifted its position in Ionis Pharmaceuticals by 99.1% in the third quarter. First Trust Advisors LP now owns 2,125,724 shares of the company’s stock worth $109,645,000 after buying an additional 1,057,960 shares during the last quarter. 85.07% of the stock is owned by hedge funds and other institutional investors.

In related news, COO Brett P. Monia sold 34,000 shares of the firm’s stock in a transaction on Friday, November 23rd. The stock was sold at an average price of $55.00, for a total value of $1,870,000.00. Following the completion of the sale, the chief operating officer now directly owns 49,841 shares in the company, valued at $2,741,255. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Patrick R. O’neil sold 19,600 shares of Ionis Pharmaceuticals stock in a transaction on Tuesday, February 5th. The stock was sold at an average price of $59.25, for a total value of $1,161,300.00. Following the sale, the senior vice president now owns 23,673 shares of the company’s stock, valued at $1,402,625.25. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 71,290 shares of company stock valued at $4,020,635. 2.44% of the stock is owned by corporate insiders.

A number of analysts recently issued reports on IONS shares. Morgan Stanley set a $46.00 price target on Ionis Pharmaceuticals and gave the stock a “hold” rating in a research report on Wednesday, November 7th. Piper Jaffray Companies set a $50.00 price target on Ionis Pharmaceuticals and gave the stock a “hold” rating in a research report on Tuesday, November 6th. Zacks Investment Research downgraded Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 9th. TheStreet upgraded Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a research report on Thursday, December 6th. Finally, Leerink Swann started coverage on Ionis Pharmaceuticals in a research report on Tuesday, November 27th. They issued a “market perform” rating and a $50.00 price target for the company. One research analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $54.25.

Shares of IONS opened at $59.10 on Tuesday. The firm has a market capitalization of $8.03 billion, a P/E ratio of 738.75 and a beta of 2.28. Ionis Pharmaceuticals Inc has a 52-week low of $39.07 and a 52-week high of $59.81. The company has a quick ratio of 7.96, a current ratio of 7.99 and a debt-to-equity ratio of 0.74.

TRADEMARK VIOLATION NOTICE: “Bank of Montreal Can Acquires 17,386 Shares of Ionis Pharmaceuticals Inc (IONS)” was originally reported by Week Herald and is owned by of Week Herald. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://weekherald.com/2019/02/12/bank-of-montreal-can-acquires-17386-shares-of-ionis-pharmaceuticals-inc-ions.html.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.

Featured Story: Why is the conference call important?

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals Inc (NASDAQ:IONS).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply